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Hepatotropic viruses such as hepatitis B virus (HBV) and hepatitis C virus (HCV) are the
major etiological agents associated with development of hepatocellular carcinoma (HCC).
Progression of HCC is a multistep process that requires sequential or parallel deregula-
tion of oncogenic and tumor suppressive pathways leading to chromosomal instability and
neoplastic phenotype. In the recent years, microRNAs (miRNAs) have carved their own
niche alongside oncogenes and tumor suppressors, owing to their innate ability to receive
and relay multiple signals. Not surprisingly, miRNAs are fast emerging as central player
in myriads of malignancies including HCC. miRNAs are reported to participate in initiation
and progression of HCC, and have also been clinically correlated with risk assessment, dis-
ease grade, aggressiveness, and prognosis. Despite extensive data available on the role of
miRNAs in HCC, there is a pressing need to integrate and evaluate these datasets to find
its correlation, if any, with causal agents in order to devise novel interventional modalities.
Through this review, we attempt to bridge the gap by consolidating the current knowledge
and concepts in the field of HCC-related miRNAs with special emphasis on HBV and HCV.
Further, we assess the potential of common as well as unique signatures that may be
useful in developing novel biomarkers and therapeutics.
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INTRODUCTION
According to a WHO estimate, hepatitis B virus (HBV) and hepati-
tis C virus (HCV) together account for ~78% of hepatocellular
carcinoma (HCC) incidence worldwide and are the second leading
cause of cancer mortality (1). High morbidity observed in HCC
is majorly attributed to lack of early detection markers and poor
prognosis, which limit the options for chemotherapy, adjuvant
therapies, or surgical procedures (2). Hence, exploration of novel
frontiers in HCC diagnosis and therapeutics remain high priority
research areas.
Recent studies suggest an indispensable role played by microR-
NAs (miRNAs) in tumor growth, and immune evasion. miRNAs
constitute a major class of well-conserved, small non-coding RNAs
that can up- or down-regulate gene expression (2, 3). Accordingly,
miRNAs can function both as tumor suppressor (TS-miR) and
oncogene (onco-miR) impacting both pro- and anti-proliferative
cascades (4). To date, nearly 2000 different miRNAs have been
identified in humans. Stability of miRNAs in blood circulation
makes them ideal candidate for use in diagnosis and treatment of
cancers. Further, tumor miRNA profiles can be helpful in defining
relevant subtypes, patient survival, treatment response, and risk
prediction (5). Given the vast repertoire of cancer-related path-
ways regulated by miRNAs, this class of biomolecules appears to
be a driving force for oncogenesis as well as “Achilles’ heel” for
therapeutic targeting. The intricate processes of miRNA biogen-
esis and maturation are easy targets of stealth hepatitis viruses
(6). In the next section, we overview how these processes are
modulated in HCC.
TRANSCRIPTIONAL REGULATION OF miRNA
The transcription of miRNA is guided by RNA polymerase (pol
II) regulators, which are often deregulated in case of liver patholo-
gies. In HBV- and HCV-associated pathogenesis, c-Myc along
with viral oncoproteins modulates miRNA expression, to create
an oncogenic milieu (7) facilitating the binding of transcriptional
repressor complexes to miRNA promoters to allow its sustained
expression (8, 9). For example, c-Myc binding to miR-122 pro-
moter (a liver-specific TS-miR) prevents RNA pol II recruitment
and H3K9 acetylation (10). c-Myc also down-regulates HNF3β,
a liver-specific transcription factor, involved in transcription of
miR-122. Since c-Myc itself is a target of certain miRNAs, the
transcriptional control of its regulators sets on a positive feedback
loop for c-Myc expression in HCC (8, 11).
c-Myc is also reported to stimulate DROSHA promoter and
thus, indirectly regulate the stability of DiGeorge syndrome
critical region gene 8 mRNA (12). Although c-Myc normally
functions as a negative regulator of miRNAs, the levels of onco-
miRs like miR-21 and miR-17-92 polycistron are elevated in
c-Myc microenvironment, which down-regulate tumor suppres-
sors (13). HCV infection per se can cause down-regulation of
TS-miR-181c by promoting the recruitment of CCAAT/enhancer
binding protein β (C/EBP-β) (14). In contrast, HBV positively
regulates miR-181a transcription – an index of poor survival
whereas it negatively regulates tumor suppressors, WIF1 and
DKK3 (controllers of Wnt signaling pathway and miR181a tar-
gets) possibly via miR181a (15–17). Inactivation of p53 in HCC
leads to down-regulation of its transcriptional targets such as
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miR-34, miR-200, and miR-15/16, which allows cell prolifera-
tion and metastasis (18). p53 inactivation also alters miRNA
biogenesis either by directly binding to DROSHA or via down-
regulation of DICER-1 (19), which may define miRNA target genes
in HCC.
POST-TRANSCRIPTIONAL REGULATION OF miRNA
Hepatitis viruses often deregulate pro-proliferative pathways in
HCC affecting phase-specific control of cyclins by miRNAs (6).
Impairment of DICER-1 is also frequently observed in HCC
combined with tumor stemness (20). Post-transcriptional reg-
ulators of Argonaute (Ago-1 and Ago-2) such as lin-41 are
over-expressed in HCC in a c-Myc dependent fashion, which
down-regulates Ago protein (21). Whereas low levels of miR-99
and miR-199a induce Ago-2 expression with consequent increase
in miR-21 (22, 23). Modulation of TGFβ signaling in HCC also
involves miRNAs to promote tumorigenesis (24, 25). Interestingly,
TGFβ effector SMAD1/5 along with RNA helicase p68 increases
the maturation rate of miR-21 and miR-199 contributing to
vascularization (25).
EPIGENETIC ALTERATIONS OF miRNA
Concordant hyper methylation of miRNA genes is frequently seen
in HCC (26, 27). The master controllers of proliferation, like c-
Met are epigenetically silenced by TS-miRs (28). An auto-feedback
loop of hyper-methylation and gene suppression is suggested for
miR-148a and miR-152 in HCC (29, 30). Acetylation status at the
pri-miRNA promoters can also suppress miRNA and help relieve
the suppressive effect of TS-miRs (31). Besides, sulfated glycolipids
can facilitate intrahepatic metastasis (32).
HBV and HCV oncoproteins may also regulate miRNA expres-
sion (33) by engaging DNA methyltransferases (DNMT), which
cause global hyper-methylation (34, 35). The HBx oncoprotein
is known to sequester the epigenetic modifier PPARγ in order
to down-regulate miR-122 in HCC (36). The HBx-mediated epi-
genetic silencing of miR-205 stabilizes HBx mRNA, and aggra-
vates disease (37). Similarly, HCV core protein can down-regulate
miR-124 and miR-345 levels by inducing DNMT expression and
abrogating apoptosis (38).
SINGLE NUCLEOTIDE POLYMORPHISM AND GENETIC
ALTERATIONS
Single nucleotide polymorphism (SNP) in the regulatory or coding
regions of miRNA is essential for onco-miR expression or silenc-
ing of TS-miRs in HCC. TS-miRs such as miR-34b/c are poorly
expressed in HCC owing to SNP RS4938723, which inhibits the
recruitment of transcription factor GATA (39). Alternately, SNPs
in the coding region of miR-196a2 and promoter of miR-106b-
25 up-regulate their expression and contribute toward HCC (40,
41). SNP in the stem–loop of pre-miR-146a affects its processing
efficiency and increases the risk of HCC (42). As miRNA genes
are often located close to fragile sites (43), their translocation is
frequently observed in many cancers. The translocation of 5′ end
of the hcr gene (encoding miR-122) to c-myc locus can cause
a massive 50-fold increase in c-Myc expression and a consequent
down-regulation of miR-122 in woodchuck hepatitis virus-related
HCC (24, 44).
Thus, miRNAs have emerged as crucial players in virus–host
interactions, where hepatitis viruses can alter miRNA biogenesis,
which in turn control key cellular pathways to establish a successful
infection as discussed in the next section.
DEREGULATION OF miRNA IN HCC
Deregulated miRNAs play a pivotal role in supporting viral
replication and perturbing key cellular processes in HBV- and
HCV-associated HCC as depicted in Figure 1.
miRNA IN THE REGULATION OF VIRAL REPLICATION
HBV and HCV engage host miRNAs to complete virus life cycle
and establish chronic infection. For example, miR-122, which is
often down-regulated in many liver pathologies, shows opposing
effects on HBV and HCV replication (45). miR-122 restricts HBV
replication by targeting cyclin G1 and allowing p53-mediated sup-
pression of viral genes (46). Paradoxically, miR-122 may support
HBV replication by down-regulating heme oxygenase-1 (HO-1), a
negative regulator of HBV transcription (47). Further, miR-1 and
miR-372 along with miR-373 can enhance HBV replication by
activating farnesoid X receptor-alpha (FXRA) and nuclear factor
I/B, respectively (48, 49). Interestingly, miR-15b can also promote
viral replication by binding to hepatocyte nuclear factor 1α and
inducing HBV enhancer 1, while down-regulated miR-15b levels
lower virus load and allow persistent HBV infection (50).
In case of HCV, however, binding of miR-122 to the internal
ribosome entry site (IRES) in the 5′-UTR of viral RNA augments
viral replication and promotes HCV translation in an Ago-2-
dependent manner (45, 51). miR-122 and miR-196 also target
HO-1 by differentially regulating its repressor Bach-1 to comple-
ment or inhibit HCV replication, respectively (52, 53). Akin to
miR-122, miR-199a-3p also binds to the IRES element and inhibits
HCV replication (53). Interestingly, miR-27a is over-expressed
in HCV cases which lowers the viral load to escape immune
surveillance through a negative feedback loop (54).
ROLE OF DEREGULATED miRNAs IN KEY CELLULAR
PROCESSES
The down-regulation of TS-miRs and concomitant elevation of
onco-miRs also affect some key cellular processes, which support
HCC.
CELL CYCLE AND PROLIFERATION
microRNAs can target cell cycle regulators to override some check-
points and support uncontrolled proliferation. For example, TS-
miR-26a targets cyclin D2/E2 that control G1/S boundary of the
cell cycle since its re-expression prevented disease progression in
a pre-clinical HCC model (55). Further, down-regulated levels of
miR-195 and miR-138 act as tumor suppressor by targeting cyclin
D1 and cyclin D3 (56, 57), while onco-miRs miR-221 and miR-222
promote tumor growth by down-regulating p27, p57, and DNA
damage inducible transcript 4 (58). The let-7 family of miRNAs,
which is down-regulated in HCC, allows cell proliferation by nega-
tively regulating STAT3 and c-Myc levels and positively regulating
p16INK4A (59, 60). MiR-99a suppresses G1 arrest of cancer cells by
targeting cyclin D1 via mTOR (61).
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FIGURE 1 | Status of micro-RNAs during hepatitis virus infection. miRNAs are up- (↑) or down-regulated (↓) in HBV- (red) or HCV-associated HCC (blue) and
interfere with key cellular pathways such as cell signaling, apoptosis, cell cycle, metastasis as well as viral replication to promote hepatocarcinogenesis.
SUPPRESSION OF APOPTOSIS
Cancer cells evade apoptosis by perturbing the balance between
pro and anti-apoptotic factors. In aggressive HCC cases, miR-
25 and miR-221 are over-expressed, which target pro-apoptotic
proteins Bim and Bmf, respectively (62, 63). Down-regulated
miR-29, miR-101, and miR-122 relieve suppression of their anti-
apoptotic targets Bcl-2, Mcl-1, and Bcl-w, respectively, leading to
increased survival in HCC (64). HBx oncoprotein down-regulates
let-7 and miR-15a/16 leading to increased anti-apoptotic activity
(65). Similarly, low levels of TS-miR-29c in HCC target tumor
necrosis factor alpha-induced protein 3 to prevent apoptosis (66).
ALTERATION OF SIGNALING PATHWAYS
Tumor suppressor PTEN, a negative regulator of PI3K/AKT sig-
naling is frequently targeted by elevated levels of miR-21,
miR-222, and miR-29a in HCC (59, 64). miR-199-3p targets
mTOR and c-Met, a HGF receptor, which controls downstream
PAK4/Raf/MEK/ERK pathway (67). Restoration of miR-199-3p
levels in hepatoma cells leads to G1 arrest, enhanced suscep-
tibility to hypoxia and drug (67). HBx suppresses the p53-
dependent activation of miR-148a, resulting in upregulation of
AKT, ERK, and activation of mTOR pathway, which promotes
tumor growth and metastasis in a HCC mouse model (68). miR-
17-5p, a member of onco-miR-17-92 cluster, activates p38-MAPK-
and Hsp27 pathway to promote cell migration and proliferation
(69). Further, miR-222 overexpression confers metastatic poten-
tial on cancer cells by activating Akt pathway (70). Besides its
pro-inflammatory role, miR-155 upregulation by HCV results in
increased nuclear accumulation of signal transducer β-catenin to
promote HCC (71).
EPITHELIAL–MESENCHYMAL TRANSITION AND METASTASIS
Prior to metastasis, tumor cells undergo epithelial–mesenchymal
transition (EMT) involving loss of E-cadherin, gain of vimentin,
collagen I, and fibronectin. miR-224, a highly expressed miRNA
in HCC, promotes tumor growth and metastasis by silencing its
target genes Cdc42, CDH1, PAK2, and BCL-2 (72). Elevated lev-
els of miR-29a and miR-148a, which target PTEN and miR-143
also down-regulate fibronectin type III domain-containing pro-
tein 3B to enhance hepatoma cell migration (73, 74). HBx engages
miR-661 and miR-373 to stimulate metastasis associated-1 pro-
tein and suppress E-cadherin, respectively (75). TS-mir-34a and
miR-125b that, respectively, target c-Met and LIN28B2 oncogenes
are inversely correlated with metastasis in HCC (76, 77). In con-
trast, miR-200c suppresses EMT of liver cancer stem cells (CSCs)
by upregulating E-cadherin, reducing vimentin, and inhibiting
metastasis through repression of neurotrophic receptor tyrosine
kinase 2 (78). Zeb1 and Zeb2 transcription factors are also targeted
by miR-141/200c to alter E-cadherin and related gene expres-
sion involved in cell polarity (79). Not surprisingly, miR-141/200c
cluster is often silenced in cancer by DNA methylation (80).
Thus, miRNAs can initiate multistep process of cancer by per-
turbing normal cell homeostasis and endowing cells with the
ability to invade and metastasize. Further, the crosstalk between
miRNAs could have a multiplier effect on their target genes as well
as drug resistance cancer phenotype.
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miRNAs AS DIAGNOSTIC MARKERS IN HCC
The lack of effective diagnostic methods for early HCC has ren-
dered the overall survival rate to a low 0–14% from the time of
clinical diagnosis (81). Modest precision of currently used diag-
nostic markers such as alpha-fetoprotein (AFP) calls for testing the
prospect of miRNAs as HCC biomarkers. Circulating miRNAs are
highly stable in serum owed to their resistance to RNAse, extreme
pH, and temperature, hence are perfect as biomarkers for detect-
ing early stage, presymptomatic diseases such as HCC as depicted
in (Figure 2).
The serum levels of miRNAs undergo alterations in HCC
patients as evident from low levels of miR-16, miR-199a, and high
levels of miR-21, miR-221, miR-222, miR-223, and miR-224 in
serum samples (5). miR-125b is down-regulated in ~70% of pri-
mary HCC samples thus could be a good candidate for diagnosis
(77). Further to expand the repertoire of prospective miRNAs in
early diagnosis of HCC, down-regulated levels of TS-miR-129 in
HCC can be detected in plasma samples from 85% of stage I HCC
patients as compared to AFP in just 10% of stage I cases (82).
Detection of HBV- or HCV-positive HCC cases, especially those
independent of cirrhosis etiology, poses a greater challenge due to
lack of biomarkers. In light of this, unique expression profile of
serum miRNAs in HBV- and HCV-positive HCC patients can serve
as a fingerprint for distinguishing between HBV and HCV cases.
Not surprisingly, miRNAs such as miR-1269, miR-224, and miR-
224-3p are significantly altered specifically in HCV-associated
HCCs (83). In contrast, miR-152 and miR-143 are aberrantly
regulated in HBV-related HCC and hence constitute potential
diagnostic markers for HBV-related HCC cases (84, 85).
Serum miRNAs enriched in exosomes can also serve as valuable
non-invasive HCC biomarkers for both diagnostic and prognostic
purposes. Indeed, recent findings have shown that serum exoso-
mal miR-21 from HCC patients provides increased sensitivity of
detection compared to whole serum (86). Interestingly, a report
on urinary miRNAs such as miR-618 and miR-650 has opened
the prospect to use them as biomarkers for early detection of
HCV-induced HCC (87).
PREDICTIVE PROGNOSTIC VALUE OF miRNAs IN HCC
It is being increasingly realized that miRNAs may possess an
edge over mRNA as prognostic indicators owed to their stabil-
ity in clinical samples and robust expression patterns. In fact,
expression profiles of a panel of 20 miRNAs can be used as
metastatic predictor, correlating with survival as well as relapse
rates in HCC (88). As indicated in Figure 2, hyper-methylation
of miRNA promoters seems to correlate with poor prognosis,
exemplified by aberrant methylation of miR-9 and corroborates
with clinical outcomes (89). Further, miR-199a/b and miR-139,
which are frequently down-regulated in most HCC patients,
show a significant correlation with poor survival (89, 90). Like-
wise, low expression of miR-124 in HCC seems to be associ-
ated with more aggressive behavior and shorter survival (89).
While, high levels of miR-22, miR-221, and C19MC miRNA
correlate with increased risk of tumor recurrence and shorter
survival (59).
Interestingly, the patterns of miRNA expression as well as SNPs
in some miRNAs seem potent as predictors of patient response
to various therapeutic strategies as well as disease risk (63). In
Chinese and Turkish populations, a positive association has been
noticed between rs11614913 (C→T) SNP in miR-196a-2 and HCC
susceptibility (91, 92). Similarly, “TTCA” insertion (rs3783553) in
3′-UTR of IL-α gene, which ablates the binding site for miR-122
FIGURE 2 | Micro-RNAs in clinical management of HCC. miRNAs with potential in HCC diagnosis, prognosis and therapy (pre-clinical studies and clinical
trials).
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and miR-378 leading to upregulation of IL1-α, correlates well with
HCC development (93).
miRNAs IN HCC THERAPY
Alterations in miRNA expression are frequently associated with
HCC disease physiology; hence miRNAs could be used as potential
druggable targets in HCC management. One of the approaches
in miRNA-based HCC therapy involves using antagomirs against
onco-miRs. Non-human primates chronically infected with HCV
when treated with locked nucleic acid (LNA) specific for miR-122
(a positive regulator of HCV replication),exhibited long-term sup-
pression of HCV viral load, supporting therapeutic use of miRNA
in HCC (2). In another pre-clinical study, involving an orthotopic
HCC mouse model, oligonucleotides targeting miR-221 inhib-
ited cell transformation and improved survival, underscoring its
potential in HCC therapeutics (5). Another potential therapeu-
tic approach for HCC treatment entails restoration of TS-miRs,
thus serving as anti-cancer agents. For instance, AAV-mediated
delivery of miR-122 and miR-26a and systemic restoration of
miR-124 can suppress tumorigenesis in animal models of HCC.
Similarly, restoration of miR-375 (2′O-methyl-modified and cho-
lesterol conjugated form) and miR-29 could inhibit tumorigenesis
in pre-clinical HCC models (2, 5).
Delivery of miRNA mimics can also be used in HCC therapy.
Indeed, a cancer-targeting miRNA mimic of miR-34 (MRX34) is
in phase I clinical trial performed by Mirna Therapeutics Inc.,
in HCC patients (5, 94). Interestingly, the mimic miRNAs are
delivered using Smarticles®, which are anionic at neural pH, but
attain cationic charge in acidic tumor environment thus minimiz-
ing off-target effects (5). Importantly, the therapeutic potential of
miR-122 antagonist, miravirsen was evident from a multi-centric
phase IIA trial, which showed sequestration of mature miR-122
and reduction of viral load (95).
Though miRNAs possess tremendous therapeutic potential for
HCC, a major concern remains their delivery system. miRNAs can
be incorporated into PEG-gylated stable nucleic acid lipid parti-
cles (SNALPS), to extend the circulation time. Further, virus-like
particle (VLP) dependent delivery gives the leverage of natural
tissue tropism, albeit with risk of eliciting immune response (5).
The emergence of miRNAs as novel clinical biomarkers is set to
change the face of HCC diagnosis and therapeutic procedures. The
proposition of miRNA profiles serving as signatures to distinguish
HCV from HBV cases, though awaiting clinical evaluation, offers
the advantage of accurate diagnosis and appropriate therapeutic
course.
CONCLUSION
The heterogeneity in individual cases of cancer including HCC
demands development of personalized medicine to ensure most
effective treatment with minimal side effects. In such a sce-
nario, unique tumor specific miRNA signatures, as reviewed here,
will help design accurate diagnostics and therapeutics tailored
to individual needs. The ease of delivering oligonucleotides to
liver and high tolerance of normal liver cells to supplements of
deficient miRNAs make HCC an ideal model to test miRNA ther-
apy (2). Preliminary evidence in non-human primates indicates
that miRNA-based treatment of chronic HCV infection provides
prolonged alleviation of virus-induced liver pathology with a high
barrier to viral resistance suggesting miRNAs may function as
better antivirals than conventional drugs (2). CSCs, resistant to
conventional chemotherapy and cause of cancer recurrence, form
the major obstacle in successful treatment of the disease. The
discovery of stemness associated miRNAs in liver cancer such as
miR-181, miR-150, and miR-548c-5p warrants further evaluation
of their potential as druggable targets in therapies against liver
CSCs (96). The gender specific discrepancy in HCC incidence can
be in part explained by microRNA signatures such as higher levels
of TS miR-26a and miR-26b in females that may provide them a
protective edge over males (97). Elevated levels of miR-18a in HCC
female patients, which suppresses protective effects of estrogen by
targeting estrogen receptor-alpha, can be used as a risk predictor
of HCC development in female population (98). Finally, the quest
for yet elusive HBV and HCV encoded miRNAs poses a challenge,
which when overcome may help in devising novel strategies to
silence viral miRNA and cure liver cancer.
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